Puma Biotechnology (PBYI) Income from Continuing Operations (2010 - 2026)

Puma Biotechnology (PBYI) has 17 years of Income from Continuing Operations data on file, last reported at 3753000.0 in Q1 2026.

• Quarterly Income from Continuing Operations fell 226.19% year-over-year to 3753000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 27808000.0 (up 265.22% YoY) and the FY2025 annual result came in at 34535000.0, up 19834.29% from the prior year.
• Income from Continuing Operations slipped to 3753000.0 in Q1 2026, from 16862000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 20317000.0 in Q3 2024 to a low of 11148000.0 in Q4 2024.
• A 5-year average of 3107823.53 and a median of 2126000.0 in 2023 frame the typical range for Income from Continuing Operations.
• Annual changes were most pronounced in 2023 — Income from Continuing Operations surged 1710.0% — and 2024, when it slumped 443.68%.
• Tracing PBYI's Income from Continuing Operations over 5 years: stood at 5151000.0 in 2022, then jumped by 341.62% to 12446000.0 in 2023, then plunged by 189.57% to 11148000.0 in 2024, then jumped by 251.26% to 16862000.0 in 2025, then plunged by 122.26% to 3753000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 3753000.0 (Q1 2026), 16862000.0 (Q4 2025), and 8844000.0 (Q3 2025), per Business Quant data.